News
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 24, 2023
A smartphone app delivering cognitive behavioral therapy to adults with type 2 diabetes cut A1c while capping inc...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 6, 2023
Prospective data from nearly 24,000 people with diabetes showed that longer diabetes duration significantly linked with an increased heart failure ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 18, 2023
Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab’s greater LDL-lowering efficacy, compared with inclisiran.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 11, 2023
A 2022 guideline for treating diabetes in people with chronic kidney disease highlighted the proven value of three underused drug classes and trigg...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 11, 2023
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more cardiovascula...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 21, 2022
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients.<...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 12, 2022
People with type 2 diabetes who used a smartphone app for cognitive behavioral therapy had a significant drop in their A1c levels.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 12, 2022
People with type 2 diabetes who tried agents from three different classes of glucose-lowering drugs usually found one they liked most. It was often...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 7, 2022
Cardiac resynchronization extended survival during 5 extra years of follow-up of the RAFT study that compared CRT-D with ICD defibrillation alone.<...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 23, 2022
The Food and Drug Administration sent an alert that it’s investigating an apparent link between the use of denosumab (Prolia) by patients on dialys...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 18, 2022
Low chloride, balanced-crystalloid IV fluid led to significantly fewer delayed graft function events, compared with saline, in a multicenter trial ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 17, 2022
Automated EHR alerts for hospitalized patients alerted clinicians when acute kidney injury developed, triggered stoppage of potentially exacerbatin...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 15, 2022
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on th...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 14, 2022
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 8, 2022
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic even...
